secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLUS THERAPEUTICS, INC. (PSTV)
CIK:        0001095981
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001193125-25-258568
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Plus Therapeutics Q3 net loss $0.04/shr; cash $16.6M; CNSide commercial launch advances
--------------------------------------------------------------------------------

- Net loss of $4.4M ($0.04/shr) vs $2.9M ($0.37/shr) in Q3 2024; operating loss $4.5M.
- Cash and investments $16.6M (up from $6.9M on June 30, 2025 and $3.6M at Dec 31, 2024).
- First national coverage agreement with UnitedHealthcare for CNSide diagnostics, covering 51M+ lives.
- Houston lab received CLIA certification, enabling Medicare/Medicaid access and commercial payor coverage.
- Positive ReSPECT-LM Phase 1 results for REYOBIQ presented at SNO/ASCO; advance payment of $1.9M from CPRIT.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1095981/000119312525258568/0001193125-25-258568-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1095981/000119312525258568/pstv-20251030.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-258568

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer